Magnesium orotate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Magnesium orotate
Accession Number
DB13786
Type
Small Molecule
Groups
Experimental
Description

Magnesium orotate is a magnesium salt of orotic acid and is poorly soluble in water. It is a source of magnesium and is used as a mineral supplement to treat Mg deficiency. Orotic acid acts as a transporter that carries magnesium into the cells. It also exhibits antioxidant properties, since it is a key intermediate in the biosynthetic pathway of pyrimidines that promotes the synthesis of enzymes which act as free radical scavengers. Experiments investigating the potential cardioprotective actions of orotic acid in pathological heart conditions are still ongoing.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
GI96W46M5A
CAS number
34717-03-8
Weight
Average: 334.483
Monoisotopic: 334.00360487
Chemical Formula
C10H6MgN4O8
InChI Key
QWLHYYKDLOVBNV-UHFFFAOYSA-L
InChI
InChI=1S/2C5H4N2O4.Mg/c2*8-3-1-2(4(9)10)6-5(11)7-3;/h2*1H,(H,9,10)(H2,6,7,8,11);/q;;+2/p-2
IUPAC Name
magnesium(2+) ion bis(2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate)
SMILES
[Mg++].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Magnesium orotate.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Magnesium orotate.
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Magnesium orotate.
AmlodipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium orotate.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Magnesium orotate.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Magnesium orotate.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Magnesium orotate.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Magnesium orotate.
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Magnesium orotate is combined with Botulinum Toxin Type A.
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Magnesium orotate is combined with Botulinum Toxin Type B.
Food Interactions
Not Available

References

General References
  1. Classen HG: Magnesium orotate--experimental and clinical evidence. Rom J Intern Med. 2004;42(3):491-501. [PubMed:16366126]
  2. Zeana C: Magnesium orotate in myocardial and neuronal protection. Rom J Intern Med. 1999 Jan-Mar;37(1):91-7. [PubMed:15523949]
  3. Rosenfeldt FL: Metabolic supplementation with orotic acid and magnesium orotate. Cardiovasc Drugs Ther. 1998 Sep;12 Suppl 2:147-52. [PubMed:9794088]
External Links
PubChem Compound
3036905
PubChem Substance
347829317
ChemSpider
2300801
ChEMBL
CHEMBL3707282
Wikipedia
Magnesium_orotate
ATC Codes
A12CC09 — Magnesium orotate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0526 mg/mLALOGPS
logP0.17ALOGPS
logP-1.2ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)2.83ChemAxon
pKa (Strongest Basic)-6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.33 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity44.11 m3·mol-1ChemAxon
Polarizability12.01 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrimidinecarboxylic acids. These are pyrimidines with a structure containing a carboxyl group attached to the pyrimidine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyrimidinecarboxylic acids
Alternative Parents
Hydropyrimidine carboxylic acids and derivatives / Pyrimidones / Vinylogous amides / Heteroaromatic compounds / Ureas / Lactams / Carboxylic acid salts / Carboxylic acids / Azacyclic compounds / Organooxygen compounds
show 5 more
Substituents
Hydropyrimidine carboxylic acid derivative / Pyrimidine-6-carboxylic acid / Pyrimidone / Hydropyrimidine / Heteroaromatic compound / Vinylogous amide / Carboxylic acid salt / Urea / Lactam / Azacycle
show 11 more
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:48 / Updated on August 02, 2018 06:58